|

INT-787 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Intercept Pharmaceuticals1

Indications

  • Alcohol Associated Hepatitis1
  • Liver Disease1

Palo Alto, California1 trial

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

Stanford Healthcare

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.